Dr. Kevin F. Ginn
Claim this profileChildren's Mercy Hospitals and Clinics
Expert in Recurrence
Expert in Tumors
36 reported clinical trials
58 drugs studied
About Kevin F. Ginn
Education:
- Obtained MD from the University of Kansas School of Medicine in 2015.
- Completed Residency in Pediatrics at Children's Mercy Hospitals and Clinics (2015-2018).
- Undertook Fellowship in Pediatric Cardiology at Children's Mercy Hospitals and Clinics (2018-2021).
Experience:
- Currently serving as a Pediatric Cardiologist at Children's Mercy Hospitals and Clinics.
Area of expertise
1Recurrence
Global LeaderStage IV
Stage I
Stage II
2Tumors
Global LeaderStage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Kevin F. Ginn is currently running
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
DFMO
for Medulloblastoma
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
Recruiting1 award Phase 2
More about Kevin F. Ginn
Clinical Trial Related7 years of experience running clinical trials · Led 36 trials as a Principal Investigator · 15 Active Clinical TrialsTreatments Kevin F. Ginn has experience with
- Cyclophosphamide
- Gemcitabine
- Ramucirumab
- Temozolomide
- Nivolumab
- Brentuximab Vedotin
Breakdown of trials Kevin F. Ginn has run
Recurrence
Neuroblastoma
Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kevin F. Ginn specialize in?
Kevin F. Ginn focuses on Recurrence and Tumors. In particular, much of their work with Recurrence has involved Stage IV patients, or patients who are Stage I.
Is Kevin F. Ginn currently recruiting for clinical trials?
Yes, Kevin F. Ginn is currently recruiting for 14 clinical trials in Kansas City Missouri. If you're interested in participating, you should apply.
Are there any treatments that Kevin F. Ginn has studied deeply?
Yes, Kevin F. Ginn has studied treatments such as Cyclophosphamide, Gemcitabine, Ramucirumab.
What is the best way to schedule an appointment with Kevin F. Ginn?
Apply for one of the trials that Kevin F. Ginn is conducting.
What is the office address of Kevin F. Ginn?
The office of Kevin F. Ginn is located at: Children's Mercy Hospitals and Clinics, Kansas City, Missouri 64108 United States. This is the address for their practice at the Children's Mercy Hospitals and Clinics.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.